The Prague Post - Who should get paid for nature's sequenced genes?

EUR -
AED 4.182614
AFN 75.167292
ALL 93.902616
AMD 417.452931
AOA 1045.510427
ARS 1708.080292
AUD 1.632807
AWG 2.052867
AZN 1.934662
BAM 1.960456
BBD 2.293638
BDT 140.5839
BHD 0.429418
BIF 3406.074805
BMD 1.1389
BND 1.473193
BOB 12.976821
BRL 5.847793
BSD 1.1388
BTN 109.079596
BWP 15.68719
BYN 3.266744
BYR 22322.439964
BZD 2.29034
CAD 1.606618
CDF 2573.91431
CHF 0.932083
CLF 0.027043
CLP 1064.32451
CNY 7.70591
CNH 7.71078
COP 3650.071993
CRC 518.12833
CUC 1.1389
CUP 30.18085
CVE 110.527514
CZK 24.169792
DJF 202.405585
DKK 7.474959
DOP 66.347582
DZD 151.856354
EGP 57.513425
ERN 17.0835
ETB 183.805055
FJD 2.539462
FKP 0.856083
GBP 0.856971
GEL 2.984175
GGP 0.856083
GHS 13.266509
GIP 0.856083
GMD 84.278841
GNF 9995.740856
GTQ 8.687596
GYD 238.205762
HKD 8.930599
HNL 30.507458
HRK 7.533595
HTG 148.832839
HUF 359.702775
IDR 20606.117666
ILS 3.484584
IMP 0.856083
INR 108.869102
IQD 1491.843273
IRR 1566129.859978
ISK 142.202809
JEP 0.856083
JMD 180.338321
JOD 0.807457
JPY 186.558657
KES 147.544381
KGS 99.597067
KHR 4603.914532
KMF 493.143631
KRW 1654.707165
KWD 0.353708
KYD 0.94895
KZT 544.641185
LAK 25810.301975
LBP 101977.706962
LKR 382.6789
LRD 206.118647
LSL 19.136667
LTL 3.362876
LVL 0.688909
LYD 7.306353
MAD 10.683174
MDL 20.156786
MGA 4880.59188
MKD 61.666192
MMK 2391.889523
MNT 4095.292812
MOP 9.197946
MRU 45.553193
MUR 54.086562
MVR 17.607592
MWK 1974.690081
MXN 19.858589
MYR 4.660351
MZN 72.787059
NAD 19.136752
NGN 1555.043387
NIO 41.909355
NOK 11.051509
NPR 174.527754
NZD 1.967706
OMR 0.437901
PAB 1.138805
PEN 3.87639
PGK 5.021928
PHP 70.016128
PKR 316.324501
PLN 4.32446
PYG 6850.270057
QAR 4.15146
RON 5.229715
RSD 117.390986
RUB 89.6864
RWF 1669.457795
SAR 4.269837
SBD 9.184827
SCR 15.384259
SDG 683.910885
SEK 11.04188
SGD 1.471681
SLE 27.618086
SOS 650.842958
SRD 43.109076
STD 23572.930532
STN 24.55822
SVC 9.964667
SZL 19.139374
THB 38.164723
TJS 10.493824
TMT 3.997539
TND 3.381216
TRY 53.953907
TTD 7.745362
TWD 36.878266
TZS 3014.102283
UAH 51.211933
UGX 4299.192125
USD 1.1389
UYU 45.748658
UZS 13722.59249
VES 844.929468
VND 29992.931451
VUV 135.718863
WST 3.133123
XAF 657.515777
XAG 0.019936
XAU 0.000283
XCD 3.077934
XCG 2.052366
XDR 0.816854
XOF 657.518671
XPF 119.331742
YER 271.228836
ZAR 19.006954
ZMK 10251.494404
ZMW 21.295579
ZWL 366.725335
  • RYCEF

    -0.0700

    18.8

    -0.37%

  • RBGPF

    0.0000

    66

    0%

  • CMSC

    0.1596

    21.88

    +0.73%

  • NGG

    -0.0600

    81.15

    -0.07%

  • VOD

    0.5600

    16.36

    +3.42%

  • RIO

    -0.4200

    91.53

    -0.46%

  • AZN

    1.7300

    171.37

    +1.01%

  • BTI

    1.4100

    62.23

    +2.27%

  • GSK

    1.7300

    53.71

    +3.22%

  • BCE

    0.5700

    21.81

    +2.61%

  • RELX

    2.1550

    37.805

    +5.7%

  • CMSD

    0.0500

    22.1

    +0.23%

  • BCC

    2.0700

    80.29

    +2.58%

  • JRI

    0.0200

    12.93

    +0.15%

  • BP

    -0.5300

    41.78

    -1.27%

Who should get paid for nature's sequenced genes?
Who should get paid for nature's sequenced genes? / Photo: Menahem KAHANA - AFP/File

Who should get paid for nature's sequenced genes?

Much of the vanilla that flavors our ice cream today is artificial, derived from the genetic signature of a plant that hundreds of years ago was known only to an Indigenous Mexican tribe.

Text size:

The plant's sequenced genomic information, available on public databases, was used as the basis for a synthetic flavoring that today competes with vanilla grown in several countries, mainly by small-scale farmers.

Few, if any, benefits of the lucrative scientific advance have trickled down to the communities that gave us vanilla in the first place.

"Wild genetic resources and pharmaceuticals ... are a multi-multi-billion dollar businesses. They clearly are profitable... that's not in dispute," Charles Barber of the World Resources Institute think tank told AFP.

"A great deal of really valuable information has fed into the system from research and utilization of wild genetic resources. And there is no mechanism currently to compensate the people where this information is coming from" in the form of digitally sequenced data, he added.

Much of the information comes from poor countries.

Fair sharing of the gains derived from digitally-stored genetic sequencing data has been a headache for negotiators at the COP16 biodiversity summit into its second week in Cali, Colombia.

At the last conference, in Montreal in 2022, 196 country parties to the UN's Convention on Biological Diversity (CBD) agreed to create a benefit-sharing mechanism for the use of digital sequence information (DSI).

Two years later, they still need to resolve such basic questions as who pays, how much, into which fund, and to whom does the money go?

- 'Cheap and very fast' -

The issue is a complex one.

There is little debate that genetic data-sharing on mostly free-access platforms is crucial for human advancement through medicine and vaccine development, for example.

But how to quantify the value of the sequenced information itself? And should the first people to discover a plant's particular usefulness be compensated?

"Sequencing technology has become so advanced that you can go with a... handheld device a little bit bigger than a cell phone and you can literally sequence a genome in an hour or two and upload it as you sequence it," Pierre du Plessis, a DSI expert and former negotiator for African countries at the CBD told AFP.

These gene sequences are then uploaded to databases which artificial intelligence can mine for potential leads for product development.

DSI is worth an estimated hundreds of billions of dollars a year. And there is a lot of it out there.

"Once the sequence is put into a public database, generally, no benefit-sharing obligations apply," Nithin Ramakrishnan, a researcher with the Third World Network, an advocacy NGO for developing countries, told AFP in Cali.

"Like when the sandalwood sequence information is available in the database whether India wants to share its sandalwood... with a cosmetic company or not, doesn't matter.

- Mandatory -

A point of contention in Cali is a demand from developing countries that payment for DSI use be mandatory, perhaps through a one-percent levy on profits from drugs, cosmetics or other products.

They also want guarantees of non-monetary benefits such as access to vaccines produced from genetic information sequenced from viruses and other pathogens.

"We want real understanding, sector-specific understanding of what non-monetary benefits will be shared and we want the system to be obligatory -- the users should have some form of obligation to share benefits," said Ramakrishnan.

Another sticking point is access for Indigenous people and local communities to DSI funds.

Developing countries want the information on genetic databases to be traceable and "answerable to governments" of the countries where it comes from, said Ramakrishnan.

But rich nations and many researchers oppose such a model which they fear will be too onerous, potentially putting the brakes on scientific pursuits that could benefit all humankind.

With such divergent points of view, observers are doubtful the Cali COP will emerge with any firm decisions on the outstanding questions by closing time on Friday.

The World Wildlife Fund has said "many more rounds of negotiations appear necessary" on DSI.

Added Barber: "I think it's not going to all get solved here."

T.Kolar--TPP